.. subcription
    .. rss channels
    .. press releases
    .. contacts


            october 19, 2019

.. in english  .. по-русски  .. latviski    

LKW Walter

CILF 2019

Busworld 2019

  .. sitemap ..


  .. publications ..


  .. news ..


  .. advertisement ..





VIA LATVIA
LKW Walter Rus
LKW Walter
 
  .. partners ..

Indiaexportnews.com

Swissport The Netherlands awarded with IATA CEIV Pharma Certification

  20.07.2017    

Swissport The Netherlands, a subsidiary of Swissport International, the world's leading provider of ground and air cargo services to the aviation industry, receives the IATA CEIV certificate for Pharmaceutical Logistics at Amsterdam Airport, Schiphol. This certification reflects Swissport’s dedication to offer excellent Life Science & Healthcare shipment handling services and will increase its contribution to the Pharma Gateway Amsterdam – a program established in 2016 to position Schiphol as the best European pharma hub.
With the increasing flow of Life Science & Healthcare shipments over the past few years, maintaining a stable and secure supply chain requires specific equipment, storage facilities, harmonized handling procedures and above all, strong cooperation among the cool chain partners. Swissport The Netherlands started to develop a dedicated product line for the handling of Life Sience & Helathcare shipments. With the recent acquisition of Terminal 9, the scope for this product line was broadened and today, all of Swissport’s operational activities in the Netherlands (both Terminal 9 and 11) are successfully awarded by the IATA CEIV certification.
“The certificate is a validation of the hard work that our team put in the pharma product”, said Jeroen Giling, Director Cargo at Swissport The Netherlands. “But that is not where we stop. In cooperation with our valued customers, we believe that the pharma product is a product line with continuous improvement cycles. This means that we will keep investing in training our staff, maintaining the best controlled pharma facilities and further develop procedures to ensure a secure and high quality pharma chain.”



.. search ..